Journal of Liver最新文献_第6页

Gallic Acid may have the Potential to Preventing the Development of Preneoplastic Lesions in Liver 没食子酸可能具有预防肝脏肿瘤前病变发展的潜力

Journal of Liver Pub Date : 2016-07-07 DOI: 10.4172/2167-0889.1000I102

L. Rodríguez-Fragoso

{"title":"Gallic Acid may have the Potential to Preventing the Development of Preneoplastic Lesions in Liver","authors":"L. Rodríguez-Fragoso","doi":"10.4172/2167-0889.1000I102","DOIUrl":"https://doi.org/10.4172/2167-0889.1000I102","url":null,"abstract":"Figure 1: Microscopic images show the potential chemopreventive effect of gallic acid. Preneoplastic lesions were developed in rats by administration of a single dose of DEN (200 mg/Kg i.p) and CCl4 (2 mL/kg i.p.) during two weeks. Preneoplastic lesions showed the presence of microscopical small-cell dysplastic focus characterized by loss of liver tissue architecture, changes in nuclear morphology, cellular pleomorphism and cell mitosis (arrows). The gallic acid (50 mg/kg p.o.) was given during five weeks previous to the induction of preneoplastic lesions. Animals pretreated with gallic acid maintained the morphological architecture of liver and no cells in mitosis were observed. In the last decades, several studies have shown the chemopreventive potential of different polyphenols in cancer [1]. Particularly, the gallic acid have shown possess several protective properties anti-cancer as anti-proliferative, pro-apoptotic and anti-tumorigenic effects in vitro and in vivo models [2]. Gallic acid has shown to have a significant chemopreventive effect on development of hepatic preneoplastic lesions in rats. Gallic acid maintains the organization of liver tissue and avoids the development of changes in nuclear morphology, reduces the cellular pleomorphism and the number of cells in mitosis (Figure 1).","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"29 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2016-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79478036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genistein Produces Hepatoprotection through Modulating EGFR Expression and Phosphorylation in Experimental Fibrosis 染料木素通过调节实验性纤维化中EGFR的表达和磷酸化产生肝保护作用

Journal of Liver Pub Date : 2016-06-21 DOI: 10.4172/2167-0889.1000196

Rodriguez Fragoso, Alvarez Ayala, García Vazquez, J. ReyesEsparza

引用次数: 6

A Typical Presentation of Hepatocellular Carcinoma 肝细胞癌的典型表现

Journal of Liver Pub Date : 2016-06-17 DOI: 10.4172/2167-0889.1000199

Chakravarty Kd, Samantaray Sp, Vishwanath Rs, Shashikala, Kumar Acp

引用次数: 1

Recurrence of hepatocellular carcinoma after living donor liver transplantation (single center experience) 活体肝移植术后肝癌复发(单中心经验)

Journal of Liver Pub Date : 2016-05-20 DOI: 10.4172/2167-0889.C1.006

Nada Eldomiaty

{"title":"Recurrence of hepatocellular carcinoma after living donor liver transplantation (single center experience)","authors":"Nada Eldomiaty","doi":"10.4172/2167-0889.C1.006","DOIUrl":"https://doi.org/10.4172/2167-0889.C1.006","url":null,"abstract":"D Liver Transplantation (DLT) started in 1995, using a donor liver with familial amyloid polyneuropathy (FAP), then increasing the pool of donors. Our Center started DLT in 2001; however cases of acquired amyloid neuropathy are increasingly being recognized following this procedure. Also our Center experience showed that the onset of FAP symptoms occurs earlier than expected. Several papers described clinical cases of acquired FAP developing 5 to 9 years after DLT. From 2001 to 2011 we have done 1078 liver transplants; we carried out 262 domino transplantations. All receptors transplanted between 2001 and 2011, were evaluated. All of them were observed and had clinical, histopathologic (salivary gland biopsy) and electrophysiologic evaluation. The symptomatic group started with sensory complaints involving their feet 4 to 10 years after DLT; three of those patients have been retransplanted to halt FAP progression and their clinical and paraclinical improvement is described. Five other patients are in the waiting list for retransplant. Patients with FAP acquired by transplantation are candidates for liver retransplantation to minimize the progression of symptoms. Liver retransplantation is considered to be a high-risk procedure but so far the results have been favorable.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76150333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 47

Portal Cavernoma as a Complication of Liver Hydatid Cyst 肝包虫病并发门静脉海绵瘤

Journal of Liver Pub Date : 2016-05-20 DOI: 10.4172/2167-0889.1000I101

B. Sanei

引用次数: 0

Short-term Survival in Acutely Decompensated Cirrhotic Patients 急性失代偿肝硬化患者的短期生存

Journal of Liver Pub Date : 2016-03-07 DOI: 10.4172/2167-0889.1000194

À. Escorsell, F. Torres, M. VegaCatalina, A. Mas, J. Ríos, M. Guevara

{"title":"Short-term Survival in Acutely Decompensated Cirrhotic Patients","authors":"À. Escorsell, F. Torres, M. VegaCatalina, A. Mas, J. Ríos, M. Guevara","doi":"10.4172/2167-0889.1000194","DOIUrl":"https://doi.org/10.4172/2167-0889.1000194","url":null,"abstract":"Aim: The present study was aimed at the early identification of the prognostic factors for 30-day mortality in acutely decompensated cirrhotic patients. Methods: Logistic regression models were used to study the predictors of mortality. Variables significant on univariate testing were included for the multivariate analysis. ROC curves were constructed. The model used retrospective data from 228 patients; and was prospectively validated among 64 patients from the Hospital Clinic: internal validation and 90 patients from Hospital Gregorio Maranon: external validation. Results: The model identified age at admission, serum concentrations of bilirubin, creatinine and sodium, and INR obtained 2 to 8 days after admission as predictors of death in this population. The resulting risk score was highly accurate: AUROC: 0.9150, 95%CI: 0.8509-0.9790 also in the internal and external validation series, but not better that the most widely used scores in hepatology: MELD: 0.8335, 95%CI: 0.7486-0.9184, MELD-Na: 0.8565, 95%CI: 0.7774-0.9356, iMELD: 0.8972, 95%CI: 0.8297-0.9648 and MESO Index: 0.8464, 95%CI: 0.7656-0.9272. The cutoff levels: LR+, LR- of the new score, MELD and MELD-Na that best predicted 30 days mortality were -0.09: 38.6, 0.51, 28: 16.7, 0.42 and 47: 12, 0.7, respectively. Conclusions: MELD, as well as new, more complicated and scanty used scores, obtained 2 to 8 days after admission allows the early and easy identification of patients with an acute decompensation of cirrhosis at high-risk of death on short-term follow-up. These scores may represent a useful tool to select the population suitable for studies to evaluate the efficacy of new therapies and stratify patients in randomized trials.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"1 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82195265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

A Histo-Pathological Study of Liver in 118 Cases of Cirrhosis 118例肝硬化肝脏组织病理分析

Journal of Liver Pub Date : 2016-02-11 DOI: 10.4172/2167-0889.1000193

N. Majethia, M. Patil, A. Kalgutkar

引用次数: 5

Early Detection of Metastases by Bone Scintigraphy in Patients with Hepatocellular Carcinoma 肝细胞癌骨显像早期检测转移灶的研究

Journal of Liver Pub Date : 2016-01-18 DOI: 10.4172/2167-0889.1000191

Xiaohui Wang, Jiang-yan Liu, Gang Chen, Yu Li, Yumin Li

引用次数: 2

Mesenchymal Stem/Stromal Cells Exert Trophic Effect on Colorectal Cancer Metastasis to the Liver 间充质干细胞/间充质细胞在结直肠癌肝转移中的营养作用

Journal of Liver Pub Date : 2016-01-01 DOI: 10.4172/2167-0889.1000135

Pratika Y Hern, Alex, er Pedroza-Gonzalez, L. V. D. Laan, M. Hoogduijn, M. Peppelenbosch, Q. Pan

{"title":"Mesenchymal Stem/Stromal Cells Exert Trophic Effect on Colorectal Cancer Metastasis to the Liver","authors":"Pratika Y Hern, Alex, er Pedroza-Gonzalez, L. V. D. Laan, M. Hoogduijn, M. Peppelenbosch, Q. Pan","doi":"10.4172/2167-0889.1000135","DOIUrl":"https://doi.org/10.4172/2167-0889.1000135","url":null,"abstract":"Colorectal Cancer (CRC) is the third most common cancer in the world. CRC tends to metastasize to the liver, which may occur in 20% to 70% of patients and represents the major cause of death. Mesenchymal Stem/stromal cells (MSCs) have shown to be able to migrate to CRC site and play an important role in tumor progression. We have previously identified a resident MSC population in the liver. Therefore, this study aims to investigate whether there is infiltration of MSCs into patient CRC Liver Metastasis (CRC-LM) and their potential effects on tumor cell growth. By culturing resected patient CRC-LM tissue, we observed the emerging of fibroblast-like cells. Further phenotype and functional characterization confirmed their bonafide MSCs features. In situ staining with a well-established MSCs marker showed a significant enrichment of candidate MSCs in patient CRC-LM, particularly the tumor-stromal area. Moreover, MSCs secreted trophic factors significantly increased colony formation and growth of a metastatic CRC cell line. In summary, we found infiltration and enrichment of MSCs in CRC-LM patient, which could in turn nourish tumor cells.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"111 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79304764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Stereotactic Ablative Radiotherapy to Treat Colorectal Liver Metastases: Ready for Prime-Time? 立体定向消融放疗治疗结直肠肝转移:准备好黄金时间了吗?

Journal of Liver Pub Date : 2016-01-01 DOI: 10.4172/2167-0889.1000139

K. Nielsen, Van der Sluis Wb, H. Scheffer, M. Meijerink, Comans Efi, B. Slotman, S. Meijer, van den Tol Mp, Haasbeek Cja

{"title":"Stereotactic Ablative Radiotherapy to Treat Colorectal Liver Metastases: Ready for Prime-Time?","authors":"K. Nielsen, Van der Sluis Wb, H. Scheffer, M. Meijerink, Comans Efi, B. Slotman, S. Meijer, van den Tol Mp, Haasbeek Cja","doi":"10.4172/2167-0889.1000139","DOIUrl":"https://doi.org/10.4172/2167-0889.1000139","url":null,"abstract":"Background: Stereotactic Ablative Radiotherapy (SABR) is a non-invasive treatment option for patients with Colorectal Liver Metastases (CRLM) ineligible for resection or thermal ablation. The aim of our study was to evaluate local control, disease progression, toxicity, complications and survival after SABR of CRLM. We also discuss the place of SABR in the treatment algorithm of CRLM. Methods: Patients with CRLM, ineligible for resection or thermal ablation and suitable for SABR, were included in our database and retrospectively analyzed. Patients with oligometastases <5 cm without the presence of other organs in the target area are eligible for SABR. Follow-up imaging was conducted at 3 and 6 months following SABR and 6-monthly thereafter. Total delivered dose per lesion was 54-60 Gy, divided over 3-12 fractions, depending on the dose constraints of normal tissues. Results: Ten patients with 13 lesions were treated with SABR. Complete local control was achieved in eight patients with 11 lesions, with a median follow-up of 20.4 months (range 7-38). Two patients showed possible local progressive disease after 12 and 25 months. No toxicity > grade 2 as a result of treatment was reported. Eight patients had died at time of analysis; median survival was 26 months. Conclusion: SABR of CRLM is safe, feasible and effective in achieving local control in patients ineligible for resection or thermal ablation. Although SABR is currently offered in a late and often palliative stage, it deserves a higher profile as a possible local treatment option and its place in the treatment algorithm should be re-evaluated.","PeriodicalId":16145,"journal":{"name":"Journal of Liver","volume":"114 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86286820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6